莫西沙星
中文名稱 | 莫西沙星 |
---|---|
中文同義詞 | 莫西沙星;1-環(huán)丙基-7-(S,S-2,8-二氮雜雙環(huán)[4.3.0]壬烷-8-基)-6-氟-8-甲氧-4-氧代-1,4-二氫-3-喹啉羧酸;莫西沙星(母核)1-環(huán)丙基-6,7-二氟-1,4-二氫-8-甲氧基-4-氧代-3-喹啉羧酸;鹽酸莫西沙星MOXIFLOXACIN HYDROCHLORIDE;莫西沙星EP雜質(zhì);(1S,6S)-1-環(huán)丙基-7-(S,S-2,8-二氮雜雙環(huán)(4.3.0)壬烷-8-基)-6-氟-8-甲氧-4-氧代-1,4-二氫-3-喹啉羧酸;(4ΑS-CIS)-1-環(huán)丙基-6-氟-1,4-二氫-8-甲氧基-7-(六氫-6H-吡咯[3,4-B] 吡啶-6-基)-4-氧-3-喹啉羧酸;莫西沙星鹽酸鹽 |
英文名稱 | Moxifloxacin |
英文同義詞 | MOXIFLOXACIN;(1'S,6'S)-1-Cyclopropyl-7-(2,8-diazabicyclo[4.3.0]non-8-yl)-6-fluoro-8-methoxy-4-oxo-1,4-dihyd;Moxifloxacin EP Impurity;Moxifloxacin Hydrochloride 2;MOXIFLOXACIN HYDROCHELORIDE;MAXIOFFOXACIN;186826-86-8 (Hydrochloride);192927-63-2 (Hydrochloride hydrate) |
CAS號 | 151096-09-2 |
分子式 | C21H24FN3O4 |
分子量 | 401.43 |
EINECS號 | 604-773-0 |
相關(guān)類別 | 抗微生物藥物;醫(yī)藥與生物化工;喹諾酮類藥物;抗感染藥物;原料藥;中間體;抗生素;抗病源性微生物藥;藥物;抗生素類;014-莫西沙星;通用生化試劑-抗生素;有機化工原料;API;化合物;intermediates;醫(yī)藥化工類;化學試劑;對照品;醫(yī)藥原料;合成抗菌藥;化工原料藥;雜質(zhì)對照品;化工原料;工業(yè)化;對照品 |
Mol文件 | 151096-09-2.mol |
結(jié)構(gòu)式 |
莫西沙星 性質(zhì)
熔點 | 203-208 C |
---|---|
比旋光度 | 23D -193° |
沸點 | 636.4±55.0 °C(Predicted) |
密度 | 1.408±0.06 g/cm3(Predicted) |
儲存條件 | 2-8°C(protect from light) |
溶解度 | 乙腈(微溶)、DMSO(微溶、加熱、超聲處理)、甲醇(微溶) |
酸度系數(shù)(pKa) | 6.43±0.50(Predicted) |
形態(tài) | 固體 |
顏色 | 灰白色至淺黃色 |
穩(wěn)定性 | 吸濕性 |
CAS 數(shù)據(jù)庫 | 151096-09-2(CAS DataBase Reference) |
EPA化學物質(zhì)信息 | 3-Quinolinecarboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-[(4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo- (151096-09-2) |
莫西沙星最常見的不良反應(yīng)包括:惡心、腹瀉、頭痛和頭暈以及心臟Q-T間期延長。
較少見的不良反應(yīng),包括全身反應(yīng)(如過敏反應(yīng)等)、心血管系統(tǒng)反應(yīng)(如高血壓、心悸)、消化系統(tǒng)反應(yīng)(如腹痛、厭食、便秘、消化不良等)、骨骼肌肉系統(tǒng)反應(yīng)(如關(guān)節(jié)痛、肌肉痛)、神經(jīng)系統(tǒng)反應(yīng)(如激動、焦慮、失眠、緊張、感覺異常等)、呼吸系統(tǒng)反應(yīng)(如呼吸困難)、皮膚軟組織系統(tǒng)反應(yīng)(如瘙癢、皮疹、多汗等)。
此外,莫西沙星還可能導致部分實驗室檢驗異常,如中性粒細胞減少,堿性磷酸酶、血清尿素氮、血清肌酐升高等。
1)如果口服莫西沙星,請固定在每天同一時間服藥,餐前餐后均可;如果靜脈滴注莫西沙星,請至少滴注90分鐘;
2)用藥后接觸陽光或紫外線,可能引起嚴重的光過敏,出現(xiàn)過度曬傷的癥狀,所以用藥期間請采取防曬措施;
3)莫西沙星可能引起頭暈等情況,用藥期間盡量避免駕駛等危險行為;
4)用藥后可能會干擾血糖,如果糖尿病患者使用,請注意監(jiān)測血糖;
用藥后可能引發(fā)嚴重副作用,如肌腱炎、肌腱斷裂、周圍神經(jīng)病變及中樞神經(jīng)系統(tǒng)副作用,或加重重癥肌無力,如果出現(xiàn)以上副作用,請停藥并聯(lián)系醫(yī)師,避免再次用藥。
Bacterial
The in vitro activities of Moxifloxacin and Amoxicillin are compared by time-kill curve and inhibition of intracellular growth experiments by using a model of bone marrow-derived mouse macrophages infected by L. monocytogenes EGDe. Moxifloxacin acts much more rapidly, beginning to exert its effects in the first 3 h and achieving complete broth sterilization within 24 h of incubation. Moxifloxacin appears to have a protective effect against macrophage lysis, as many cells are still viable after 24 h of incubation.
Moxifloxacin (12 mg/kg; intravenous injection; once-three times per day; for 7 days; white male Wistar rats) treatment every 8 hours is accompanied by longer survival. Tissue cultures 30 hours after bacterial challenge shows considerably less bacterial overgrowth in the spleens and lungs of moxifloxacin-treated than in salinetreated animals and without being toxic.
Animal Model: | 144 white male Wistar rats (18-22 weeks; 300-400 g) infected Stenotrophomonas maltophilia |
Dosage: | 12 mg/kg |
Administration: | Intravenous injection; once per day, twice per day, three times per day; for 7 days |
Result: | Showed considerably less bacterial overgrowth in the spleens and lungs and without being toxic. |
安全信息
危險品標志 | Xn |
---|---|
危險類別碼 | 22-40 |
安全說明 | 36/37 |
毒害物質(zhì)數(shù)據(jù) | 151096-09-2(Hazardous Substances Data) |
更新日期 | 產(chǎn)品編號 | 產(chǎn)品名稱 | CAS號 | 包裝 | 價格 |
---|---|---|---|---|---|
2024/11/11 | XW1510960921 | 莫西沙星 | 151096-09-2 | 250MG | 106元 |
2024/11/08 | HY-66011A | 莫西沙星 Moxifloxacin | 151096-09-2 | 100mg | 500元 |